Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 423

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 423
---
31, 2023 and 2022, using Black-Scholes with the following assumptions:

|                          |     | December 31, |      |   |     |      |      |   |
|                          |     |         2023 |      |   |     | 2022 |      |   |
| Risk-free interest rate  |     |              |  5.4 | % |     |      |  4.7 | % |
| Expected life (in years) |     |              | 0.25 |   |     |      |  1.0 |   |
| Expected dividend yield  |     |              |    - | % |     |      |    - | % |
| Expected volatility      |     |              | 65.9 | % |     |      | 85.0 | % |

At December 31, 2023 and 2022, the preferred
stock warrants were exercisable and remained outstanding.

<div align='center'>F-62

CERo Therapeutics, Inc.

Notes to Financial Statements</div>

NOTE 9 – COMMON STOCK

In September 2016, the Company issued 8,500,000
shares of common stock to the founders (“Founder Stock”) in exchange for consideration payable by cash and by transfer of
certain technology and related rights owned by the founders. The Founder Stock vested ratably over a four-year period following the date
of issuance. As of December 31, 2022, all Founders Stock was fully vested.

The holders of common stock are also entitled
to receive dividends whenever funds are legally available, when and if declared by the Board of Directors. As of December 31, 2023,
dividends have never been declared.

At December 31, 2023 and 2022, the Company
had reserved common stock for future issuance as follows:

|                                                                  |     | December 31, |            |     |      |            |
|                                                                  |     |         2023 |            |     | 2022 |            |
| Convertible preferred stock, authorized but not yet issued       |     |              |  1,849,738 |     |      |  1,849,738 |
| Conversion of convertible preferred stock issued and outstanding |     |              | 27,920,467 |     |      | 27,920,467 |
| Stock Incentive Plan:                                            |     |